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Introduction
COVID-19: Epidemiological and clinical context
The pandemic caused by the severe acute respiratory syn-
drome coronavirus 2 (SARS-CoV-2) infection-coronavirus dis-
ease 2019 (COVID-19)-started at the end of 2019, affecting all 
the countries in the world. This was associated with serious 
medical, social, political, and economical consequences. Till 
date (08.06.2020), more than seven million persons are infected 
worldwide, with close to 500.000 casualties (1). The clinical pic-
ture is dominated by flu-like respiratory and general symptoms 
(such as fever, fatigue, loss of smell, cough, myalgia, diarrhea, 
and dyspnea). The disease is mild in the majority of cases. How-
ever, interstitial pneumonia and respiratory failure can occur in 
15%–20% of patients. In the case of respiratory failure, dyspnea 
associated with hypoxemia is characteristic, and progression 
to more severe forms requiring mechanical ventilation could be 
rapid. The involvement of other organs, systems, and homeostatic 
mechanisms–liver, kidney, heart and circulatory system, nervous 
system, and coagulation system (hypercoagulability)–also occur 
frequently. The definitive diagnosis of active infection is provided 
by the detection of the virus in the patient’s nasopharyngeal se-
cretions, using real-time reverse transcription polymerase chain 
reaction (rRT-PCR) assay. The clinical management of COVID-19 
is still evolving and includes antiviral (mostly empirical and still 
investigational), and immunomodulatory therapies, as well as 
intensive care measures (such as mechanical ventilation) for 
those in critical conditions (2, 3).
Pathophysiological background of pulmonary involvement 
and respiratory failure in SARS-CoV-2 infection
Lung involvement is the main pathological feature of CO-
VID-19, and is responsible for respiratory failure, the leading 
cause of death. The lung injury produced by SARS-CoV-2 starts 
with viral attachment to angiotensin converting enzyme 2 (ACE2) 
receptors, present on the apical surface of respiratory epithelial 
cells in the conductive airways. The infected respiratory epithe-
lial cells are the source of the local and systemic (to distant or-
gans) viral spread, a process which is facilitated by inflammation 
and alveolar-capillary damage (4). ACE2 is a membrane-associ-
ated aminopeptidase expressed in the pulmonary epithelium, 
vascular endothelia, renal and cardiovascular tissue, and the 
epithelia of small intestines and testes (5). Beyond replication 
in the epithelial cells, SARS-CoV-2 down-regulates the expres-
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sion of ACE2 receptors, which results in increased angiotensin 
II levels and induction of further lung injury via angiotensin II re-
ceptor type 1 stimulation. Lung damage is also promoted by the 
so-called cytokine storm (hyperinflammatory response), a part 
of the patient’s immune reaction (4, 6).
On microscopy, lung injury in COVID-19 is characterized by 
alveolar hyaline membrane formation, fibrin exudates, epithe-
lial damage, vascular congestion, and diffuse-type II pneumo-
cyte hyperplasia. The pulmonary interstitium is infiltrated by 
monocytes, macrophages, and lymphocytes. In more advanced 
phases of the disease, thickening of the alveolar walls and inter-
stitium can be observed, with intraalveolar organization caused 
by fibroblastic proliferation and extracellular matrix formation 
(7). An important and specific pathological finding in COVID-19 
patients is the extensive microangiopathy of pulmonary vessels, 
associated with microthrombosis and neoangiogenesis (8).
The morphological lesions developed in the lungs have 
characteristic (although not specific) correspondents on chest 
computed tomography images: ground-glass opacities reflect-
ing edema of the alveolar septa, hyperplasia of the interstitium, 
partial filling of airspaces, or their combination; crazy-paving 
patterns corresponding to hyperplasia of inter- and intra-lob-
ular interstitial tissue; and consolidations, which correspond 
to advanced alveolar damage, and can appear in the center of 
ground-glass opacities or be patchy. The lesions are frequently 
localized in the lower lobes of both lungs, subpleurally. The 
global aspect in the early stages of lung injury corresponds to 
the diagnosis of viral pneumonia. In the case of progression, 
later stages of the disease can be accompanied by typical mor-
phological and imaging pictures of acute respiratory distress 
syndrome (ARDS) (9).
Recent data support that vascular damage and dysfunction 
play an essential role in the development of respiratory failure 
and ARDS in COVID-19 patients. Insufficient hypoxic vasocon-
striction response in poorly ventilated pulmonary areas causes 
hypoxemia by ventilation/perfusion mismatch. In the early phase 
of respiratory failure, the lung has low elastance, the ventilation-
to-perfusion (VA/Q) ratio is low, and there is a low lung recruit-
ability (type L phenotype). Progression of pulmonary lesions 
causes, in the later phase, the morpho-functional picture of a 
classical ARDS, with high pulmonary elastance, high right-to-
left shunt and high lung recruitability (type H phenotype). These 
types of ARDS have to be considered when setting a mechanical 
ventilation strategy and parameters (tidal volume, positive end-
expiratory pressure level, etc.) (10, 11).
Pulmonary involvement could be accompanied and aggravat-
ed by cardiac, liver, renal, and nervous system dysfunctions, as 
well as the prothrombotic state prone to cause thromboembolic 
complications. 
Subsequently, we present the principal technical, practical 
and clinical data regarding the use of lung ultrasound (LUS)-an 
emerging bedside imaging tool-in evaluating pulmonary involve-
ment in COVID-19 patients.
General principles of lung ultrasound examination
Despite the initial caveats due to the presence of air in the 
lungs, LUS has proven over time to be useful in the imaging of 
pulmonary structures (pleura, subpleural space, and paren-
chyma), gaining an important diagnostic and prognostic role in 
pulmonary medicine and cardiology. LUS came in handy in the 
recent  COVID-19 era (12).
LUS is performed in most cases by using a convex ultrasound 
probe (with a variable frequency between 2 and 5 MHz). On the 
other hand, a linear probe (with a variable frequency between 4 
and 12 MHz) allows a better definition of the pleural line and the 
proximal subpleural space. It is ideal when the machine has a 
lung preset, otherwise, an abdominal preset with a depth of 8–10 
cm is used. This may differ depending on the patient's body con-
stitution. The gain and focus should be adjusted, and positioned 
to optimize the visualization of the pleural line and lung sliding. 
The mechanical index should be kept low, and the frame rate 
maximized (13, 14).
When scanning the lungs, a distinction should be made 
between healthy and pathological parenchyma. A-lines are 
horizontal artifacts, which can be seen in parallel with the 
thin, hyperechogenic pleural line that moves synchronously 
with respiratory movements. These artifacts are caused by the 
normally aerated lung. In the case of lungs with reduced air 
content (such as pulmonary congestion, acute interstitial lung 
injury, fibrosis), A-lines disappear, and B-lines appear. These 
are comet-tail-shaped, laser-beam like, reverberation artifacts, 
which begin at the pleural line and penetrate downwards to the 
bottom of the scanning sector, their motion being synchronous 
with breathing movements. B-lines are oriented vertically (when 
using a linear probe) or radially (when using a convex probe) 
and are hyperechoic. In the case of worsening congestion due 
to left heart failure, the number of B-lines increase, and pleural 
effusion can occur. If there is an inflammatory process in the 
lung interstitium, the number of B-lines increases, but because 
of the changes which can take place in the pleura and the ad-
jacent pulmonary parenchyma, this could be accompanied by 
pleural line irregularity and disruption, and the appearance of a 
subpleural consolidation pattern. The latter appears on LUS as a 
“tissue-like” echogenic mass in the lung, arising from the pleural 
line in the absence of pleural effusion, and having a nearly iden-
tical echodensity with the liver (13-17).
The methodology of examination: Our practice
To avoid the nosocomial spread of the virus and minimize 
the risk of infection of healthcare workers, portable (hand-held) 
ultrasound devices are recommended for LUS examination in 
COVID-19 patients. They are easier to carry for bedside exami-
nations, and can easily be disinfected and protected (by using a 
plastic foil for example) (18, 19).
For the LUS in our patients, General Electric V-Scan 2 (linear 
probe of 3.4–8.0 MHz) and Philips Lumify (convex probe of 2–5 
MHz and linear probe of 4–12 MHz) hand-held ultrasound de-
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vices were used. The examination requisites, including the ultra-
sound device(s), disinfectant, ultrasound gel, disposable paper 
towel, a pack of gloves, and plastic foil were prepared on a push-
able 4-wheel mobile table (Fig. 1). This preparation enabled the 
examination to be performed by one operator, at bedside. Dur-
ing the examination, the ultrasound recordings were saved for 
off-line analysis and further validation by two properly trained 
ultrasonographers. 
The LUS was performed with the patient in a sitting position, 
except for mechanically ventilated patients, who were examined 
in the supine position. The best examination protocol in COVID-19 
patients is still subject to debate, however, we used a previously 
developed, standardized scanning protocol. Sixteen areas were 
scanned per patient, with a recording duration of 5–6 seconds 
per area, containing at least one complete respiratory cycle. The 
average time of LUS per patient was 7 minutes (13, 14, 20).
Between the two possible positions of the ultrasound probe 
in relation to the ribs, longitudinal (perpendicular) and transver-
sal (parallel), the latter was our preferred approach. The chest 
wall was divided into 4 regions on both sides by 5 anatomical 
lines (parasternal, anterior and posterior axillary, scapular and 
paravertebral). Every region was further divided into an upper 
and a lower area (Fig. 2). Although the posterior chest wall (ar-
eas 7 and 8 on both sides) was not always accessible for ex-
amination as in the case of mechanically ventilated patients, we 
always tried to visualize this region (by tilting the patient on the 
side), because of the frequent occurrence of pulmonary lesions 
in this site, especially in the early phase of the disease. The se-
quence of examination was left to right, anterior to posterior and 
top-down (14, 17-19). The worksheet (score table) used in our 
department with the scanning areas is presented in Table 1.
Lung ultrasound patterns in COVID-19 patients
In the articles published so far, SARS-Cov-2 infection does 
not seem to produce characteristic or unique image patterns on 
LUS. The findings vary depending on the severity and nature of 
the inflammatory process in the lung. Thus, the spectrum of ul-
trasound changes ranges from normal-looking lung parenchyma 
and the image of simple interstitial involvement to consolida-
tion (pneumonia) patterns. The type and characteristics of ul-
trasound findings correlate well with the pathological changes 
taking place in the lungs (19, 20).
The following patterns can be observed on LUS in COVID-19 
patients (14, 19-21):
a) decrease/loss of air content: disappearance of A-lines;
b) presence of interstitial inflammatory infiltrates: B-lines (com-
et tails), which can be multiple and grouped; if they are con-
fluent, the aspect is called the “waterfall” sign;
c) pleural involvement: thickening of the pleural line with irregu-
larities (including “skip” lesions which represent the disrup-
tion of the pleural line) and reduced pleural sliding; 
d) subpleural consolidations: ecogenic masses with multifocal, 
translobar and non-translobar distribution, sometimes asso-
ciated with mobile bronchoaerograms; 
e) pleural effusion (low incidence);
Figure 1. The worktable with the hand-held ultrasound device and the 
auxiliary tools
Figure 2. Example of the scanning areas (left side)
Table 1. Scanning worksheet (score table) with the areas of LUS examination. The final results are introduced in the lower row
 Posterior Postero-lateral Antero-lateral Anterior Anterior Antero-lateral Postero-lateral Posterior
Upper R7 R5 R3 R1 L1 L3 L5 L7
Lower R8 R6 R4 R2 L2 L4 L6 L8
                           Total A-BBC score:                               Nr. of pleural involvement - “p”:                            Pleural effusion:
Symbols: R - right; L- left; 1–8–the number of areas
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A special attention is required to differentiate B-lines from Z-
lines. The latter are artifacts, which have a less defined starting 
point, do not move with lung sliding and do not influence A-lines. 
They are wider, less ecogenic than the pleural line, and do not 
extend to the bottom of the ultrasound image sector (12). 
The A-BBC score (each letter represents a pattern) has been 
introduced recently for better characterization and quantifica-
tion of pulmonary involvement by LUS. The components of this 
score are presented in Table 2. It is important to mention, that 
in the case of B1 and B2 severity classes, close attention must 
be paid to the pleural line. If pleural lesions are present, the let-
ter “p” is precised, which means pleural involvement, a sign of 
disease severity (14, 20). The LUS patterns corresponding to the 
components of A-BBC score system are presented in Figure 3. 
The LUS images were obtained from COVID-19 patients hospi-
talized in our Department. Table 3 shows an example of a com-
pleted scanning worksheet (score table).
Clinical applications
There are three major clinical applications of LUS in the set-
ting of COVID-19: (1) primary screening and diagnosis of lung in-
volvement in patients presenting at the emergency room with a 
suspicion of COVID-19, (2) daily routine, or as occasion requires 
(such as deterioration of oxygen saturation), and monitoring of 
patients hospitalized in general wards, and (3) daily and regular 
monitoring of patients (with or without mechanical ventilation) 
in the intensive therapy wards. It is important to emphasize that 
LUS is frequently completed in clinical practice by point of care 
ultrasound, limited transthoracic echocardiographic (TTE) or 
critical care echo examinations (22, 23). 
In the emergency setting, the application of LUS examination 
can reduce the contact time with patients, lowering the risk of 
disease transmission. In the case of a suggestive clinical pic-
ture, the presence of typical ultrasound findings can estabilish 
the diagnosis of COVID-19. In the case of positive LUS, even after 
a negative first rRT-PCR test, the patient has to be isolated and 
retested. Also, the severity of LUS lesions can be used as a basis 
for an initial risk stratification. 
In hospitalized patients, sequential LUS provides an efficient 
tool for monitoring the progression or regression of pulmonary 
lesions. Variations in the number and aspect of B-lines and areas 
of alveolar congestion (consolidation) are most important in this 
regard. The reappearance of A-lines is a sign of parenchymal 
healing. Monitoring of pulmonary involvement by LUS also has 
an important role in the evaluation of the efficacy of different 
treatment modalities, and can help in or trigger therapeutic de-
cisions. In critically ill patients, LUS can predict the chance of 
Table 2. The A-BBC score system and its components
Severity class Score Definition
A 0 point Normal pleural line and well-ventilated lung with the presence of a maximum of 3 B-lines.
B1 1 point More than 3 B-lines, their confluence not exceeding more than 50% of the image sector, lack of
  clear subpleural involvement.
B2 2 points Confluent B-lines that cover more than 50% of the image sector, lack of clear subpleural lesions.
C 3 points Presence of consolidation which can be associated with broncho-aerogram.
Table 3. Example of a completed scanning worksheet (score table). The final results are in the lower row
 Posterior Postero-lateral Antero-lateral Anterior Anterior Antero-lateral  Postero-lateral Posterior 
Upper 1 1p 2p 3 0 0 1 1
Lower 1 1 2 2p 0 1 1p 1
                           Total A-BBC score: 18                           Nr. of pleural involvement - “p”: 4                                   Pleural effusion: NO
Figure 3. Images demonstrating the main changes on LUS in COVID-19 
patients (the elements of A-BBC score). I–score 0 (class A): normal 
pleural line, 1 B-line, presence of A-lines; II–score 1 (class B1); 
normal pleural line, >3 B-lines; III - score 2 (class B2): multiple B-lines 
(”waterfall” sign), pleural involvement (”p”); IV - score 3 (class C): 
subpleural involvement (consolidation) and disruption of pleural line; 
V–Z-lines: vertical, wider lines, less ecogenic than the pleural line, 
without clinical significance
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weaning from mechanical ventilation. Finally, it is important to 
mention that ultrasound findings always have to be interpreted 
while considering the clinical picture and blood oxygenation pa-
rameters (23-25).
Conclusion
In the last decade, LUS has gained a remarkable place in 
the bedside evaluation of cardiac and pulmonary patients. The 
main abilities of LUS rely on the visualization of pulmonary tis-
sue (interstitium, parenchyma) and pleura in diverse pathologi-
cal processes. In COVID-19, pulmonary lesions have a key role 
in determining the clinical course and prognosis. LUS as an easy 
imaging technique, could therefore be considered an important 
tool in the hands of clinicians for the diagnosis and follow-up of 
pulmonary involvement, and for making proper and timely thera-
peutic decisions.
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